327 filings
Page 9 of 17
SUPPL
pb685vcz83s
30 Nov 18
Supplemental materials (foreign)
5:23pm
6-K
e61fdzza6 mzdf
8 Nov 18
Current report (foreign)
4:04pm
6-K
2z6uu8eeme3pk77
8 Nov 18
Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development
4:02pm
6-K
tkrwf9
25 Sep 18
Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis
4:04pm
6-K
7y47zhj29 txoldd
9 Aug 18
Current report (foreign)
4:05pm
6-K
l7tq7k5
9 Aug 18
Aurinia Reports Second Quarter Financial Results and Operational Highlights
4:03pm
6-K
rgq3e9tw
11 Jul 18
Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
4:01pm
6-K
3fa8cc
25 Jun 18
Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin
11:32am
6-K
vkc ymq8m0c0ut288
22 Jun 18
Aurinia Announces Results of Annual General Meeting
4:30pm
S-8
agwhrs3aqb42b
8 Jun 18
Registration of securities for employees
5:16pm
6-K/A
emi2r gsvbjan4lk7q
17 May 18
Current report (foreign) (amended)
12:00am
6-K
808gs0bq
16 May 18
Notice of Annual General Meeting of Shareholders
4:14pm
6-K
3lvieb
10 May 18
Current report (foreign)
4:06pm
6-K
sbyhb s0kbgc
10 May 18
Aurinia Reports First Quarter Financial Results and Operational Highlights
4:03pm
SUPPL
4m1ho2ja
6 Apr 18
Supplemental materials (foreign)
12:00am
EFFECT
7vooz4tk
29 Mar 18
Notice of effectiveness
12:00am
F-10/A
lmjwqop2
26 Mar 18
Registration of securities (Canada) (amended)
12:00am
6-K
koupq7qn8qv7eeb
15 Mar 18
Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
12:00am
40-F
blfte54
15 Mar 18
Annual report (Canada)
12:00am
6-K
wana ncel8ifrmcvbs
23 Feb 18
Aurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors
12:00am